Published in Br J Clin Pharmacol on March 01, 2002
Precision of skin prick and puncture tests with nine methods. J Allergy Clin Immunol (1991) 1.50
One-year treatment of chronic urticaria with mizolastine: efficacy and safety. URTOL study group. J Eur Acad Dermatol Venereol (2000) 1.40
A double-blind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: suppressive effects on histamine-induced wheals and flares during 24 hours in normal subjects. J Allergy Clin Immunol (1990) 1.16
Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet (1999) 1.10
Twenty-four hours of activity of cetirizine and fexofenadine in the skin. Ann Allergy Asthma Immunol (2001) 0.99
Cetirizine. A reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders. Drugs (1993) 0.91
New insights into the second generation antihistamines. Drugs (2001) 0.91
Activity of ebastine (10 and 20 mg) and cetirizine at 24 hours of a steady state treatment in the skin of healthy volunteers. Fundam Clin Pharmacol (2001) 0.91
Pharmacodynamics and pharmacokinetics of mizolastine (SL 85.0324), a new nonsedative H1 antihistamine. Ann Allergy (1992) 0.89
Can an antihistamine delay appearance of hay fever symptoms when given prior to pollen season? Allergy (1997) 0.87
Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults. Ann Allergy (1993) 0.86
Cetirizine. A review of its pharmacological properties and clinical potential in allergic rhinitis, pollen-induced asthma, and chronic urticaria. Drugs (1990) 0.84
The antiallergic effects of antihistamines (H1-receptor antagonists). J Allergy Clin Immunol (1992) 0.83
Comparison of the efficacy, safety, and onset of action of mizolastine, cetirizine, and placebo in the management of seasonal allergic rhinoconjunctivitis. MIZOCET Study Group. Ann Allergy Asthma Immunol (1999) 0.83
Nasal effect of cetirizine and loratadine at 24 hours in patients with allergic rhinitis. Am J Ther (1998) 0.83
Efficacy and safety of mizolastine in seasonal allergic rhinitis. The Rhinase Study Group. Ann Allergy Asthma Immunol (1996) 0.82
Study of cardiac repolarization in healthy volunteers performed with mizolastine, a new H1-receptor antagonist. Br J Clin Pharmacol (1999) 0.80
Consistency and efficacy of cetirizine (10 mg) versus ebastine (20 mg) at 4 h on skin reactivity. Eur J Clin Pharmacol (1999) 0.80
Inhibition of histamine-induced skin wheal and flare after 5 days of mizolastine. J Clin Pharmacol (1996) 0.79
Effect of mizolastine on visceral sensory afferent sensitivity and inflammation during experimental colitis. Arzneimittelforschung (1998) 0.79
Comparative therapeutic effect and safety of mizolastine and loratadine in chronic idiopathic urticaria. URTILOR study group. Eur J Dermatol (2000) 0.79
Comparing the H1 profile of second-generation antihistamines. Allergy (2000) 0.79
Anti-inflammatory properties of mizolastine after oral administration on arachidonic acid-induced cutaneous reaction in the rat. Arzneimittelforschung (1998) 0.79
Consistency of the efficacy of cetirizine and ebastine on skin reactivity. Ann Allergy Asthma Immunol (1998) 0.79
Treatment of chronic urticaria with cetirizine dihydrochloride a non-sedating antihistamine. Br J Dermatol (1988) 0.79
Inhibition of histamine-induced nasal obstruction by cetirizine in allergic rhinitis. Br J Clin Pharmacol (1992) 0.78
Comparison of cetirizine and terfenadine in the treatment of chronic idiopathic urticaria. Ann Allergy (1990) 0.77
Comparative wheal and flare study of mizolastine vs terfenadine, cetirizine, loratadine and placebo in healthy volunteers. Br J Clin Pharmacol (1995) 0.77
Mizolastine: antihistaminic activity from preclinical data to clinical evaluation. Clin Exp Allergy (1999) 0.77
Cetirizine. An updated review of its pharmacological properties and therapeutic efficacy. Clin Rev Allergy (1993) 0.77
The metabolism and pharmacokinetics of 14C-cetirizine in humans. Ann Allergy (1987) 0.77
Rapid and sustained efficacy of mizolastine 10 mg once daily in seasonal allergic rhinitis. J Int Med Res (1998) 0.77
Rapid symptom relief in rhinitis. Clin Exp Allergy (1999) 0.76
Lack of subsensitivity to mizolastine over 8-week treatment. Allergy (1996) 0.76
Mizolastine is effective and well tolerated in long-term treatment of perennial allergic rhinoconjunctivitis. Riperex Study Group. J Int Med Res (1999) 0.76
Onset of action in the nasal antihistaminic effect of cetirizine and loratadine in patients with allergic rhinitis. Allergy (1997) 0.76
Comparative tolerability of second generation antihistamines. Drug Saf (1999) 0.76
Lack of behavioural toxicity of mizolastine: a review of the clinical pharmacology studies. Clin Exp Allergy (1999) 0.76
Humoral and cellular responses to histamine and pollen allergen in a skin chamber model: effect of mizolastine. Ann Allergy Asthma Immunol (2000) 0.76
Pharmacological modulation by cetirizine and ebastine of the cutaneous reactivity to histamine. Dermatologica (1991) 0.76
Inhibitory effects of orally or sublingually administered cetirizine on histamine-induced weals and flares and their correlation with cetirizine plasma concentrations. J Int Med Res (1991) 0.76
Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins. Virology (1987) 7.92
Fatty acid degradation in Escherichia coli. An inducible acyl-CoA synthetase, the mapping of old-mutations, and the isolation of regulatory mutants. Eur J Biochem (1969) 5.58
Application of a fluorogenic PCR assay for typing and subtyping of influenza viruses in respiratory samples. J Clin Microbiol (2000) 3.40
ato Operon: a highly inducible system for acetoacetate and butyrate degradation in Escherichia coli. Eur J Biochem (1972) 2.12
The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy (2008) 1.96
Loss of envelope antigens of HTLV-III/LAV, a factor in AIDS pathogenesis? Lancet (1985) 1.84
Spontaneous apoptosis of dendritic cells is efficiently inhibited by TRAP (CD40-ligand) and TNF-alpha, but strongly enhanced by interleukin-10. Eur J Immunol (1995) 1.78
Gouleako virus isolated from West African mosquitoes constitutes a proposed novel genus in the family Bunyaviridae. J Virol (2011) 1.73
Human-immunodeficiency-virus-type-1-encoded Vpu protein is phosphorylated by casein kinase II. Eur J Biochem (1992) 1.70
Morphogenesis and morphology of HIV. Structure-function relations. Arch Virol (1989) 1.63
Indigenous hepatitis E virus infection of a plasma donor in Germany. Vox Sang (2009) 1.60
The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma. Int J Epidemiol (1997) 1.59
A comparative study of the avian reticuloendotheliosis virus: relationship to murine leukemia virus and viruses of the avian sarcoma-leukosis complex. Virology (1975) 1.59
Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A (2004) 1.53
Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer (2000) 1.48
Reported incidence of occupational asthma in France, 1996-99: the ONAP programme. Occup Environ Med (2003) 1.47
Small cell carcinoma of the pleura. A case report. Lung Cancer (1996) 1.47
Antimycoplasma properties and application in cell culture of surfactin, a lipopeptide antibiotic from Bacillus subtilis. Appl Environ Microbiol (1997) 1.45
Migratory pulmonary infiltrates in a patient treated with sotalol. Eur Respir J (1997) 1.45
Salbutamol, terbutaline and pirbuterol allergy in an asthmatic patient. Allergy (2007) 1.42
Mechanism of inactivation of enveloped viruses by the biosurfactant surfactin from Bacillus subtilis. Biologicals (1997) 1.42
Do nasal mast cells release histamine on stimulation with substance P in allergic rhinitis? Clin Exp Allergy (1994) 1.42
Highly sensitive and specific fluorescence reverse transcription-PCR assay for the pseudogene-free detection of beta-actin transcripts as quantitative reference. Clin Chem (1999) 1.35
Human herpesvirus 6A DNA Is detected frequently in plasma but rarely in peripheral blood leukocytes of patients after bone marrow transplantation. J Infect Dis (2000) 1.34
The organization of the envelope projections on the surface of HIV. Arch Virol (1988) 1.30
Immunoprecipitation of herpes simplex virus type 1 antigens with different antisera and human cerebrospinal fluids. Arch Virol (1977) 1.30
Variability of IgE reactivity profiles among European mite allergic patients. Eur J Clin Invest (2008) 1.29
Fatty acid degradation in Escherichia coli: requirement of cyclic adenosine monophosphate and cyclic adenosine monophosphate receptor protein for enzyme synthesis. J Bacteriol (1974) 1.26
Detection of human cytomegalovirus DNA by real-time quantitative PCR. J Clin Microbiol (2000) 1.24
Neurogenic mechanisms in bronchial inflammatory diseases. Allergy (2004) 1.22
Quaternary ammonium compounds and occupational asthma. Int Arch Occup Environ Health (2000) 1.22
Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study. J Acquir Immune Defic Syndr (2001) 1.21
Increase of virus yields and releases of Borna disease virus from persistently infected cells. Virus Res (1985) 1.20
The nerve growth factor and its receptors in airway inflammatory diseases. Pharmacol Ther (2007) 1.16
Examining landscape factors influencing relative distribution of mosquito genera and frequency of virus infection. Ecohealth (2009) 1.16
Antiviral and hemolytic activities of surfactin isoforms and their methyl ester derivatives. J Antibiot (Tokyo) (1999) 1.16
Hepatitis B and C among Berlin dental personnel: incidence, risk factors, and effectiveness of barrier prevention measures. Epidemiol Infect (2000) 1.15
Arachidonic acid metabolites and airway epithelium-dependent relaxant factor. J Pharmacol Exp Ther (1987) 1.13
Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy (2008) 1.12
Determination of the size of HIV using adenovirus type 2 as an internal length marker. J Virol Methods (1994) 1.12
Prediction of mite allergen levels by guanine measurements in house-dust samples. Allergy (1993) 1.10
Epitope mapping of monoclonal antibodies against human immunodeficiency virus type 1 structural proteins by using peptides. J Virol (1989) 1.10
Activation of the TNF alpha-p55 receptor induces myocyte proliferation and modulates agonist-evoked calcium transients in cultured human tracheal smooth muscle cells. Am J Respir Cell Mol Biol (1996) 1.09
[Is chemotherapy with cisplatin useful in non small cell bronchial cancer at staging IV? Results of a randomized study]. Bull Cancer (1991) 1.08
Sodium-potassium ATPase, calcium, and immunological histamine release. Biochem Pharmacol (1983) 1.07
Inhibition of infectious human immunodeficiency virus type 1 particle formation by Gag protein-derived peptides. J Gen Virol (1994) 1.06
Characterization of muscarinic receptors in human, guinea pig and rat lung. J Pharmacol Exp Ther (1989) 1.05
Mite allergens: an overview. Eur Ann Allergy Clin Immunol (2011) 1.04
[Occupational asthma: studies and principal etiologic factors]. Bull Eur Physiopathol Respir (1986) 1.04
Prevalence and risk factors for HBV, HCV and HDV infections among injecting drug users from Rio de Janeiro, Brazil. Braz J Med Biol Res (1999) 1.04
Bovine herpesvirus 1: differentiation of IBR- and IPV-viruses and identification and functional role of their major immunogenic components. Arch Virol (1985) 1.03
MHC-antigens: constituents of the envelopes of human and simian immunodeficiency viruses. Z Naturforsch C (1988) 1.03
Occupational asthma in France: a 1-yr report of the observatoire National de Asthmes Professionnels project. Eur Respir J (2002) 1.02
Inhibition of viral replication by monoclonal antibodies directed against human immunodeficiency virus gp120. J Gen Virol (1992) 1.02
Monoclonal antibodies directed against human immunodeficiency virus (HIV) gag proteins with specificity for conserved epitopes in HIV-1, HIV-2 and simian immunodeficiency virus. J Gen Virol (1988) 1.01
Quantitative IgE inhibition experiments with purified recombinant allergens indicate pollen-derived allergens as the sensitizing agents responsible for many forms of plant food allergy. J Allergy Clin Immunol (2000) 1.01
The influence of intramolecular disulfide bonds on the structure and function of Semliki forest virus membrane glycoproteins. Virology (1980) 1.01
Epithelial modulation of tracheal smooth muscle response to antigenic stimulation. J Appl Physiol (1985) (1986) 1.01
Sodium-potassium ATPase inhibition potentiates compound 48/80-induced histamine secretion from mast cells. Br J Pharmacol (1984) 1.01
Dose-dependent effects of endotoxins on allergen sensitization and challenge in the mouse. Clin Exp Allergy (2004) 1.00
Focus-immunoassay for Borna disease virus-specific antigens. Zentralbl Veterinarmed B (1984) 1.00
Effects of cyclic AMP- and cyclic GMP- phosphodiesterase inhibitors on immunological release of histamine and on lung contraction. Br J Pharmacol (1981) 1.00
[Intestinal spirochetosis in HIV infection: prevalence, isolation and morphology of spirochetes]. Dtsch Med Wochenschr (1990) 1.00
HLA class II alleles in isocyanate-induced asthma. Am J Respir Crit Care Med (1994) 0.99
Mechanisms of epithelial barrier impairment in HIV infection. Ann N Y Acad Sci (2000) 0.99
Twenty-four hours of activity of cetirizine and fexofenadine in the skin. Ann Allergy Asthma Immunol (2001) 0.99
Noninvasive methods for assessment of airway inflammation in occupational settings. Allergy (2009) 0.99
Validation of the sterilization procedure of allogeneic avital bone transplants using peracetic acid-ethanol. Biologicals (2001) 0.98
A double-blind, placebo controlled trial of solidified benzyl benzoate applied in dwellings of asthmatic patients sensitive to mites: clinical efficacy and effect on mite allergens. J Allergy Clin Immunol (1993) 0.98
The functional activity of alpha 1-proteinase inhibitor in bronchoalveolar lavage fluids from healthy human smokers and non-smokers. Clin Chim Acta (1983) 0.98
Increased prevalence of asthma and allied diseases among active adolescent tobacco smokers after controlling for passive smoking exposure. A cause for concern? Clin Exp Allergy (2004) 0.97
The antibody response to the HIV-1 specific "out" (vpu) protein: identification of an immunodominant epitope and correlation of antibody detectability to clinical stages. AIDS Res Hum Retroviruses (1990) 0.97
[Endobronchial aspergillosis associated with a carcinoid tumor]. Rev Mal Respir (1990) 0.97
Fatal poxvirus outbreak in a colony of New World monkeys. Vet Pathol (2006) 0.97
Epithelial uptake and transport of cell-free human immunodeficiency virus type 1 and gp120-coated microparticles. J Virol (1998) 0.95
Prognostic value of histology in patients with non-small cell lung cancer. Lung Cancer (1997) 0.95
Sensitivity of HIV antibody detection in saliva. Med Microbiol Immunol (1993) 0.95
The cerebrospinal fluid of rabbits infected with Borna disease virus. Arch Virol (1977) 0.95
Inhaled substance P induces activation of alveolar macrophages and increases airway responses in the guinea-pig. Neuropeptides (1993) 0.95
Meat wrapper's asthma: identification of the causal agent. Clin Allergy (1980) 0.94
Increased immunoglobulin G production by short term cultured duodenal biopsy samples from HIV infected patients. Gut (1998) 0.94
Medical Indoor Environment Counselor (MIEC): role in compliance with advice on mite allergen avoidance and on mite allergen exposure. Allergy (2003) 0.93
Plaque/focus immunoassay: a simple method for detecting antiviral monoclonal or other antibodies and viral antigens in cells. J Immunol Methods (1984) 0.93
Abnormal predominance of IgG in HIV-specific antibodies produced by short-term cultured duodenal biopsy specimens from HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 0.93
Nerve growth factor levels and localisation in human asthmatic bronchi. Eur Respir J (2002) 0.93
Conservation of a gene cluster including glycoprotein B in bovine herpesvirus type 2 (BHV-2) and herpes simplex virus type 1 (HSV-1). Virology (1988) 0.92
Comparison of the efficacy of virus inactivation methods in allogeneic avital bone tissue transplants. Cell Tissue Bank (2001) 0.92
Human bronchial smooth muscle cells in culture produce stem cell factor. Eur Respir J (1999) 0.92
Clinical and inflammatory responses to exogenous tachykinins in allergic rhinitis. Am Rev Respir Dis (1991) 0.92
Monoclonal antibodies directed against tick-borne encephalitis virus with neutralizing activity in vivo. Acta Virol (1994) 0.92
The structure of the Rous sarcoma virus glycoprotein complex. Arch Virol (1978) 0.92
Monoclonal antibodies against herpes simplex virus type 1-infected nuclei defining and localizing the ICP8 protein, 65K DNA-binding protein and polypeptides of the ICP35 family. J Gen Virol (1988) 0.91
New insights into the second generation antihistamines. Drugs (2001) 0.91
Activity of ebastine (10 and 20 mg) and cetirizine at 24 hours of a steady state treatment in the skin of healthy volunteers. Fundam Clin Pharmacol (2001) 0.91
Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy (1999) 0.91
Transbronchial needle aspiration in the diagnosis of sarcoidosis. Chest (1984) 0.91
Borna disease virus-specific antigens: two different proteins identified by monoclonal antibodies. Vet Immunol Immunopathol (1991) 0.91